Annexin Pharmaceuticals AB (publ) is a Sweden-based biotechnology company. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV has the ability to protect and repair the blood vessels, as well as counteract the inflammation. In addition, the Company has a comprehensive patent portfolio for the treatment of diseases that occur because of damage and blood vessel inflammation. The production process is patented. The Company maintains a cell line for manufacture of Annexin A5. The Companyâ€™s main shareholders are Mikael Loenn, Frostskog AB, Medirista AB and Colinex Capital AB.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Net sales - Rate of surprise

Company calendar

Delayed Nasdaq Stockholm Other stock markets			5-day change	1st Jan Change
- ^SEK	-.--%		-3.17%	-

07-16	Calendar, Thursday, July 16	FW
06-23	Annexin Pharmaceuticals AB Updates On Continuous Promising Data From The Nexus Study Demonstrating Improvement Of Retinal Perfusion In Both Dr And Rvo	CI

Market Cap	91.42M 9.48M 8.29M 7.65M 7.05M 13.29M 913M 13.58M 35.96M 447M 35.62M 34.84M 1.54B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	91.42M 9.48M 8.29M 7.65M 7.05M 13.29M 913M 13.58M 35.96M 447M 35.62M 34.84M 1.54B	EV / Sales 2026 *	1.21x	EV / Sales 2027 *	-
Free-Float	42.81%	Yield 2026 *	-	Yield 2027 *	-

07-16	Calendar, Thursday, July 16	FW
06-23	Annexin Pharmaceuticals AB Updates On Continuous Promising Data From The Nexus Study Demonstrating Improvement Of Retinal Perfusion In Both Dr And Rvo	CI
06-15	Five stocks hit new 52-week lows on the Stockholm Stock Exchange today	FW
06-10	Calendar Wednesday June 10	FW
06-09	Calendar Wednesday June 10	FW
05-21	Annexin Pharmaceuticals AB Investigates Three-Day Anxv Treatment Regimen in Patients with Rvo	CI
05-11	Annexin receives German approval for ANXV clinical trial	RE
05-11	Annexin Pharmaceuticals AB Receives Clinical Trial Approval for ANXV in Germany, Widening Patient Recruitment in the Nexus Study	CI
04-23	Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-22	Annexin Pharmaceuticals AB Provides Update on ANXV Clinical Study in Retinal Vein Occlusion and Diabetic Retinopathy	CI
04-13	Annexin Pharmaceuticals Mulls SEK20 Million Rights Issue; Bridge Facility Secured	MT
04-13	Annexin secures financing through bridge loan facility, plans rights issue	RE
03-26	Seven stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW

07-03	Annexin's rights issue 98 percent subscribed	AQ
06-23	Annexin updates on continuous promising data from the NEXUS study – demonstrating improvement of retinal perfusion in both DR and RVO	AQ
06-15	The subscription period in Annexin Pharmaceuticals’ rights issue begins today	AQ
06-10	Annexin Pharmaceuticals publishes Information document in connection with forthcoming rights issue	AQ
06-05	Annexin Pharmaceuticals to present at Aktiedagarna in Stockholm on June 10	AQ

Annexin Pharmaceuticals AB (publ) Stock Nasdaq Stockholm

Stocks

ANNX BTA

SE0013748894

Biotechnology & Medical Research

Valuation: Annexin Pharmaceuticals AB (publ)

Latest news : Annexin Pharmaceuticals AB (publ)

Press Releases: Annexin Pharmaceuticals AB (publ)

News in other languages: Annexin Pharmaceuticals AB (publ)

Managers and Directors: Annexin Pharmaceuticals AB (publ)

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

Net sales - Rate of surprise

Manager	Title	Age	Since
Anna Frostegård CTO	Chief Tech/Sci/R&D Officer	53	2015-12-31
Nils Anders Haegerstrand CEO	Chief Executive Officer	65	2018-12-31
Susanne Andersson DFI	Director of Finance/CFO	55	2023-04-10

Director	Title	Age	Since
Carl-Fredrik Lindner CHM	Chairman	50	2016-12-31
Curt Mikael von Euler-Chelpin BRD	Director/Board Member	73	-
Jan Nilsson CHM	Chairman	77	2023-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ANNEXIN PHARMACEUTICALS AB (PUBL)	-.--%	-3.17%	-	-	9.48M
ARGENX SE	+0.11%	-0.82%	+55.86%	+57.23%	53.83B
WUXI APPTEC CO., LTD.	-7.17%	-4.39%	+42.72%	+73.70%	52.1B
INSMED INCORPORATED	+0.80%	-6.31%	+5.62%	+413.12%	23.48B
BIONTECH SE	-0.09%	-0.01%	-16.85%	-16.17%	23.13B
WUXI BIOLOGICS (CAYMAN) INC.	+3.46%	+2.52%	+36.64%	-5.41%	19.36B
GENMAB A/S	+0.13%	-1.71%	+34.46%	-32.43%	17.56B
PHARMAESSENTIA CORPORATION	-5.16%	-7.00%	+168.44%	+291.24%	15.2B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.62%	0.00%	+33.47%	+643.91%	14.83B
EXELIXIS, INC.	+0.43%	-1.03%	+25.75%	+186.18%	14.06B
Average	-0.53%	-2.62%	+42.90%	+179.04%	25.95B
Weighted average by Cap.	-1.43%	-2.36%	+41.57%	+137.72%

	2026 *	2027 *
Net sales	75.6M 7.84M 6.85M 6.33M 5.83M 10.99M 755M 11.23M 29.74M 370M 29.46M 28.81M 1.27B	-
Net income	19.6M 2.03M 1.78M 1.64M 1.51M 2.85M 196M 2.91M 7.71M 95.91M 7.64M 7.47M 330M	-58M -6.02M -5.26M -4.85M -4.47M -8.43M -579M -8.62M -22.81M -284M -22.6M -22.1M -977M
Net Debt	-	-